Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia
Journal
Cancer
Date Issued
2022-12-20
Author(s)
Yu, Chih-Hsiang
Su, Ying-Hui
Coustan-Smith, Elane
Wu, Gang
Cheng, Chao-Neng
Lin, Kai-Hsin
Wu, Kang-Hsi
Chen, Shu-Huey
Huang, Fang-Liang
Wang, Jinn-Li
Yen, Hsiu-Ju
Ho, Wan-Ling
Liu, Yen-Lin
Chang, Chia-Ching
Lin, Ze-Shiang
Lin, Chien-Yu
Chen, Hsuan-Yu
Ni, Yu-Ling
Lin, Dong-Tsamn
Yang, Jun J
Pui, Ching-Hon
Abstract
This study analyzed data from two consecutive protocols for children newly diagnosed with acute lymphoblastic leukemia (ALL) to determine the clinical impact of minimal/measurable residual disease (MRD) and recently identified tumor genetic subtypes.
Subjects
Taiwan Pediatric Oncology Group; chemotherapy regimen; childhood acute lymphoblastic leukemia; genetic subtypes; minimal residual disease
SDGs
Type
journal article